top of page

Products

Synolis VA - Injectable Joint Supplement
Designed For Your Movements

Synolis VA is a Swiss-made joint injection supplement that fights the effects of osteoarthritis (OA) by mimicking the properties of synovial fluid.

​

It's proprietary technology includes a high molecular weight hyaluronic acid (HA) combined with a high concentration of sorbitol.

​

Delivered in either a 2ml and 4ml sterile syringe, Synolis VA provides optimal treatment flexibility. 

SYNOLIS-KEYVISUAL-SOCCER.png
Synolis, inspired by synovial fluid
SYNOLIS-PACKAGINGS.png

Synolis is designed to adapt to the needs of the joint during movement. 
 

  • Patented cross-over frequency of 0.4Hz similar to a healthy synovial fluid.

  • During movement, the rheological properties of a healthy synovial joint switches from viscous to elastic to ensure a seamless and pain free movement. Patients suffering from OA loose this viscoadaptivity.

​

Synolis supplements the joints by enhancing the viscoelastic properties of the synovial fluid

  • High Molecular Weight

  • Non-crosslinked

  • Non-animal origin / bio fermentation

​

  • Protects HA from degradation

  • Physico-chemical properties (Osmolality, pH) close to synovial fluid

  • Excellent Safety Profile

Clinical Proven Efficacy
SYNOLIS-ASSETS-3_PICTOS.png
SYNOLIS-ASSETS-3_PICTOS.png
SYNOLIS-ASSETS-3_PICTOS.png
SYNOLIS-ASSETS-3_PICTOS.png
SYNOLIS-ASSETS-3_PICTOS.png

A single injection of Synolis 80/160 can significantly reduce pain in patients with osteoarthritis of the knee¹²

Significant improvement in function and stiffness in patients with knee osteoarthritis receiving a single injection of Synolis 80/160¹²

Synolis is a safe and well tolerated treatment with less than 0.01% adverse event rates ¹²³⁴⁵

Synolis Characteristics
NaHA
(sodium hyaluronate)
Sorbitol

  • Concentration: 20mg/ml

  • Biofermentation origin (non-animal)

  • Pharmaceutical grade product

  • Molecular weight: 2MDa in the sterilized product

  • Non-crosslinked

​

   Concentration: 40mg/ml​

SYNOLIS-ASSETS-3_PICTOS.png
Treatment Options
References

  1. Cortet, B. et al. (2021): Non-Inferiority of a Single Injection of Sodium Hyaluronate Plus Sorbitol to Hylan G-F20: A 6-Month Randomized Controlled Trial. In Advances in Therapy 38 (5), pp.2271–2283. DOI: 10.1007/s12325-021-01648-3

  2. Cucurnia, I. et al. (2021): Patient-reported outcomes of intra-articular hyaluronic acid for osteoarthritis of the knee: a prospective and multicentric case series. In Musculoskeletal surgery 2022 Sep;106(3):303-310. Epub 2021 Jan 24. DOI: 10.1007/s12306-021-00698-8

  3. Dott. Moretti, L. et al. (2021): Outcome clinici post infilitrazione one shot di acido ialuronico ad alto peso molecolare con aggiunta di sorbitolo in pazienti con hip diseases, follow up 6 mesi.Poster SIOT, 13-14 September 2021

  4. Migliore A, et al. (2014): Duration of symptom relief after intra-articular injection of hyaluronic acid combined with sorbitol (anti-ox-vs) in symptomatic hip osteoarthritis. Int J Immunopathol Pharmacol 2014;27:245-252. DOI: 10.1177/039463201402700211

  5. Radenne, F. (2014): Pain relief, functional recovery and associated medical treatments reduction in large-scale population with osteoarthritis receiving injections of viscosupplement incorporating high concentration of sorbitol. Osteoarthritis and Cartilage, Volume 22, Supplement, S407, April 2014. DOI: 10.1016/j.joca.2014.02.764 

  6. Gavard, S. An innovative hyaluronic acid product for viscosupplementation in patients with osteoarthritis. Osteoarthritis and Cartilage, Volume 21, Supplement , S302-S303, April 2013 DOI:https://doi.org/10.1016/j.joca.2013.02.631

  7. Mongkhon, J.-M., et al. (2014): Sorbitol-modified hyaluronic acid reduces oxidative stress, apoptosis and mediators of inflammation and catabolism in human osteoarthritic chondrocytes.Inflamm Res. 2014 Aug;63(8):691-701. Epub 2014 May 25. DOI: 10.1007/s00011-014-0742-4

  8. Heisel, J., et al. (2012): Hyaluronic acid with sorbitol-efficacy and tolerability of intra-articular treatment for osteoarthritis of the knee. In Orthopädie und unfallchirurgie zeitschrift 1, pp. 1–7 

  9. Post Market Surveillance (PMS) Data on file

  10. PMCF2-4mL – “An efficacy and safety 6-months study of SYNOLIS VA 80/160 and SYNOLIS VA 40/80 in the treatment of symptomatic knee osteoarthritis” (data on file)

Disclaimer

The products listed above are reserved for use by licensed medical practitioners only and in approved geographical regions where marketing authorization has been provided by governing Health Authorities. Certain products may not be approved for sale in all countries. 

bottom of page